



AUSPICES  
GITMO - Gruppo Italiano per il Trapianto di Midollo Osseo  
SIE – Società di Ematologia  
SIES – Società di Ematologia Sperimentale

# T-CELL BASED IMMUNOTHERAPIES FOR LYMPHOID MALIGNANCIES

Presidents  
Paolo Corradini  
Marco Ruella  
Pier Luigi Zinzani



BOLOGNA, ROYAL HOTEL CARLTON  
**June 20-22, 2022**

# Faculty

## SCIENTIFIC SECRETARIAT

### Paolo Corradini

Fondazione IRCCS - Istituto Nazionale dei Tumori  
Cattedra di Ematologia  
Università degli Studi di Milano  
Via Venezian, 1 - 20133 Milano, Italy

### Marco Ruella

Perelman Center for Advanced Medicine  
Department of Medicine  
University of Pennsylvania  
3400 Civic Center Blvd - 19104 Philadelphia, PA, USA

### Pier Luigi Zinzani

IRCCS Azienda Ospedaliero-Universitaria di Bologna  
Istituto di Ematologia "Lorenzo e Ariosto Seràgnoli"  
Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale  
Università di Bologna  
Via Massarenti, 9 - 40138 Bologna, Italy

Jeremy S.	Abramson	Boston, MA, USA	Marco	Ruella	Philadelphia, PA, USA
Ranjana H.	Advani	Stanford, CA, USA	Barbara	Savoldo	Chapel Hill, NC, USA
Pamela	Allen	Chicago, IL, USA	Stephen J.	Schuster	Philadelphia, PA, USA
Stephen M.	Ansell	Rochester, NY, USA	Tanya	Siddiqi	Duarte, CA, USA
Philippe	Armand	Boston, MA, USA	Yujin	Song	Beijing, China
Sarit	Assouline	Montreal, Canada	Jakub	Svoboda	Philadelphia, PA, USA
Rajat	Bannerji	New Brunswick, NJ, USA	Corrado	Tarella	Milano, Italy
Rafet	Basar	Houston, TX, USA	Catherine	Thieblemont	Paris, France
Maria Chiara	Bonini	Milano, Italy	Max S.	Topp	Würzburg, Germany
Peter	Borchmann	Köln, Germany	Michael	Wang	Houston, TX, USA
Elizabeth L.	Budde	Duarte, CA, USA	Pier Luigi	Zinzani	Bologna, Italy
Carmelo	Carlo-Stella	Rozzano-MI, IT			
Cristiana	Carniti	Milano, Italy			
Bruce D.	Cheson	Washington, PA, USA			
Graham	Collins	Oxford, United kingdom			
Paolo	Corradini	Milano, Italy			
Catherine S.M.	Diefenbach	New York, NY, USA			
Peter	Dreger	Heidelberg, Germany			
Andres J.M.	Ferreri	Milano, Italy			
Nathan H.	Fowler	Houston, TX, USA			
Joseph	Fraietta	Philadelphia, PA, USA			
Weidong	Han	Beijing, China			
Alex F.	Herrera	Duarte, CA, USA			
Martin	Hutchings	Copenhagen, Denmark			
Caron A.	Jacobson	Boston, MA, USA			
Saad	Kenderian	Rochester, MN, USA			
George	Lenz	Münster, Germany			
Franco	Locatelli	Roma, Italy			
Frederick L.	Locke	Tampa, FL, USA			
Pei-Hua	Lu	Beijing, China			
Craig H.	Moskowitz	Miami, FL, USA			
Loretta	Nastoupil	Houston, TX, USA			
Sattva S.	Neelapu	Houston, TX, USA			
Martin	Pule	London, United Kingdom			
Concetta	Quintarelli	Napoli, Italy			
Carlos A.	Ramos	Houston, TX, USA			

02.00 pm Welcome and introduction  
P. Corradini, M. Ruella, P.L. Zinzani

## CHECKPOINT INHIBITORS

### SESSION I – EFFICACY SO FAR

Chairman: **C.H. Moskowitz**

02.10 pm Hodgkin lymphoma  
C.H. Moskowitz

02.30 pm Primary mediastinal large B-cell lymphoma  
P.L. Zinzani

02.50 pm Diffuse large B-cell and follicular lymphoma  
S.M. Ansell

### SESSION II – LECTURES ON HOT TOPICS

Chairman: **P.L. Zinzani**

03.10 pm Mechanisms of failure  
P. Armand

03.30 pm Duration of treatment and the concept of retreatment  
C.H. Moskowitz

03.50 pm The role and the activity of checkpoint inhibitors  
post allotransplant  
P. Armand

04.10 pm Efficacy of chemotherapy after failed anti-PD1  
therapy for relapsed/refractory Hodgkin lymphoma  
B.D. Cheson

### SESSION III – NEXT STEPS: COMBINATIONS

Chairman: **P. Armand**

In pretreated patients:

04.30 pm Anti PD1 + brentuximab vedotin  
A. Herrera

04.50 pm “Double and triplet” concept  
C.S.M. Diefenbach

05.10 pm AFM13 plus pembrolizumab  
S.M. Ansell

05.30 pm Carmelizumab and decitabine  
W. Han

In untreated patients:

05.50 pm Nivolumab + AVD  
S.M. Ansell

06.10 pm Pembrolizumab + AVD  
P. Allen

### SESSION IV – NOVEL CHECKPOINT INHIBITORS

Chairman: **B.D. Cheson**

06.30 pm Macrophage checkpoint: anti-CD47 antibody  
Hu5F9-G4 (magrolimab) with rituximab  
R.H. Advani

06.50 pm Avelumab (anti-PD-L1)  
G. Collins

07.10 pm ...and data from the last anti-PD1:  
tislelizumab and sintilimab  
Y. Song

Tuesday, June 21, 2022

## BISPECIFIC ANTIBODIES

### SESSION V – BISPECIFIC ANTIBODIES IN LYMPHOMAS

Chairman: **C. Carlo-Stella**

- 08.30 am Mosunetuzumab  
S. Assouline
- 08.50 am Epcoritamab  
M. Hutchings
- 09.10 am Odronextamab  
R. Bannerji
- 09.30 am Glofitamab  
M. Hutchings
- 09.50 am IGM-2323  
E.L. Budde

### SESSION VI – LECTURES ON HOT TOPICS

Chairman: **G. Lenz**

- 10.10 am Combination of bispecific and CAR-T  
S.J. Schuster
- 10.30 am Long term outcomes of CAR-T vs. bispecific  
M. Topp
- 10.50 am *Coffee break*

## CAR-T CELL

### SESSION VII – CLINICAL DATA IN LARGE B-CELL LYMPHOMAS

Chairmen: **P. Corradini, M. Ruella**

#### In third line

- 11.10 am Axi-cel/Tisa-cel/Liso-cel:  
Ing-term outcomes of pivotal trials  
J.S. Abramson, S.S. Neelapu, S.J. Schuster
- 11.40 am Zamtocabtagene autoleucel  
P. Borchmann
- 12.00 pm Real-life data from US  
C.A. Jacobson, L. Nastoupil
- 12.30 pm Real-life data from Europe  
C. Thieblemont
- 12.50 pm Real-life data from the CAR-T bags products  
C. Carniti
- 01.10 pm How to predict disease response in LBCL?  
S.J. Schuster
- 01.30 pm *Lunch*

Tuesday, June 21, 2022

**SESSION VIII – FUTURE INDICATIONS IN LARGE B-CELL LYPHOMAS**

Chairmen: **A.J.M. Ferreri, C. Tarella**

In second line

02.30 pm Axi-Cel  
F.L. Locke

02.50 pm Other anti-CD19  
J.S. Abramson

In first line

03.10 pm ZUMA-12  
S.S. Neelapu

**SESSION IX – LECTURES ON HOT TOPICS**

Chairman: **F. Locatelli**

03.30 pm Toxicity  
S.S. Kenderian

03.50 pm Mechanisms of resistance or relapse  
M. Ruella

04.10 pm Autologous SCT versus CAR-T  
J. Svoboda

04.30 pm CAR-T vs. Allo SCT in LBCL  
P. Dreger

04.50 pm Adoptive T-cell therapy: beyond CAR-T cells  
M.C. Bonini

05.10 pm Gene editing  
J. Fraietta

05.30 pm CAR-T cell therapy for CD30-positive lymphomas  
C. Quintarelli

Wednesday, June 22, 2022

**SESSION X – OTHER LYMPHOMAS AND CLL**

Chairman: **N.H. Fowler**

08.30 am Mantle cell lymphoma  
M. Wang

08.50 am Hodgkin lymphoma  
C.A. Ramos

09.10 am Follicular lymphoma  
N.H. Fowler, C.A. Jacobson

09.40 am T-cell lymphomas  
M. Pule

10.00 am CD30-directed CAR-T co-expressing CCR4 in CTCL  
B. Savoldo

10.20 am Chronic lymphocitic leukemia  
T. Siddiqi

10.40 am *Coffee break*

# Wednesday, June 22, 2022

## SESSION XI – THE NEXT STEPS...

Chairmen: **C.A. Jacobson, S.J. Schuster**

11.00 am	CAR-T cell in China P. Lu
11.20 am	Allogenic CAR-T-cell F.L. Locke
11.40 am	CAR expressing NK cells for cancer retargeting R. Basar
12.00 pm	Early CAR-T modulation with antibodies or small molecules M. Ruella
12.20 pm	Conclusions and arrivederci

## General information

### Meeting venue

Royal Hotel Carlton  
Via Montebello, 8 - 40121 Bologna, Italy  
Phone: +39 051 249361 - [www.royalhotelcarltonbologna.com](http://www.royalhotelcarltonbologna.com)

### Official language

English

### Registration fee

€ 180,00 (Italian VAT included)

The registration fee includes: conference kit, participation in the scientific sessions, certificate of attendance, coffee breaks, lunches.

### CME credits

An Italian CME application has been submitted as follows:

- Provider Studio ER Congressi SRL: ID 828-332656
- No. 11,2 CME credits for Physicians (disciplines: hematology, oncology, internal medicine), Biologists and Chemists.
- Educational objective: "linee guida - protocolli - procedure".

### European CME credits

The program of the meeting has been reviewed and approved for CME accreditation by the European Board for Accreditation in Hematology (EBAH), an independent accreditation body endorsed by EHA. The EBAH Unit has approved this educational activity for no. 16 CME credits for Physicians, Biologists and Chemists. To request credits, please fill out the form and return it to the registration desk at the end of the meeting. We remind you that it is necessary to have an EBAH-CME account in order to claim for credits. Attendees can create an EBAH-CME account registering on the website: <http://ebah.org>.

### Badge

All registered participants, speakers and sponsors will be given a badge which must be worn in order to be admitted to the scientific sessions.

### Certificate of attendance

A certificate will be given to all participants at the end of the meeting.

### Slides

Slides must be in English. Slides should be handed to the slide center two hours before the beginning of the session.

## Acknowledgments

Celgene |  Bristol Myers Squibb™  
Company

 GILEAD |  Kite

 MSD

 NOVARTIS

---

 Roche

---

abbvie

AstraZeneca 

 BeiGene

 Genmab

 igm  
biosciences®

 TESSA  
THERAPEUTICS

ORGANIZING SECRETARIAT

Studio E.R. Congressi

Via De' Poeti, 1/7 - 40124 Bologna, Italy

Phone: +39 051 4210559 - E-mail: [ercongressi@ercongressi.it](mailto:ercongressi@ercongressi.it) - [www.ercongressi.it](http://www.ercongressi.it)